Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Subscribe To Our Newsletter & Stay Updated